News
ONVO
1.030
+1.98%
0.020
Weekly Report: what happened at ONVO last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ONVO last week (0311-0315)?
Weekly Report · 03/18 11:01
Weekly Report: what happened at ONVO last week (0304-0308)?
Weekly Report · 03/11 10:58
Weekly Report: what happened at ONVO last week (0226-0301)?
Weekly Report · 03/04 11:01
Weekly Report: what happened at ONVO last week (0219-0223)?
Weekly Report · 02/26 11:12
Weekly Report: what happened at ONVO last week (0212-0216)?
Weekly Report · 02/19 11:14
12 Health Care Stocks Moving In Monday's Intraday Session
Renalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. Regencell Bioscience stock rose 39.91% and Sangamo Therapeutics stock moved upwards by 26.04% in the same session. Other gainers include Genenta Science and T2 Biosystems. AN2 Therapeutic stock decreased by 75.0% during the session.
Benzinga · 02/12 17:31
Weekly Report: what happened at ONVO last week (0205-0209)?
Weekly Report · 02/12 11:05
Organovo: Fiscal Q3 Earnings Snapshot
Barchart · 02/08 16:52
Organovo Holdings Unveils Corporate Presentation Online
TipRanks · 02/08 09:13
Organovo Holding: Current report
Press release · 02/07 14:19
Weekly Report: what happened at ONVO last week (0129-0202)?
Weekly Report · 02/05 11:12
Weekly Report: what happened at ONVO last week (0122-0126)?
Weekly Report · 01/29 11:02
Organovo files for $150M mixed shelf
Seeking Alpha · 01/26 22:15
Organovo Holding: Registration statement under Securities Act of 1933
Press release · 01/26 22:12
Organovo Presents FXR314 3D Human Tissue Model Findings
FXR314 improved measures of epithelial barrier function and fibrotic activity in 3D models of human Crohn's disease and ulcerative colitis. The study was published in the Journal of Clinical Pharmacology and Experimental Biology. It is the first to show the activity of FXR314 in the disease.
Benzinga · 01/25 13:06
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
Presentation of preclinical data related to the company's FXR314 development program in its proprietary 3D human tissue models of Crohn's disease and ulcerative colitis to be held January 25-27, 2024 in Las Vegas. Organovo Holdings, Inc. Is a clinical stage biotechnology company focused on developing FXR 314 in inflammatory bowel disease.
Barchart · 01/25 07:05
Weekly Report: what happened at ONVO last week (0115-0119)?
Weekly Report · 01/22 11:06
Weekly Report: what happened at ONVO last week (0108-0112)?
Weekly Report · 01/15 11:02
Weekly Report: what happened at ONVO last week (0101-0105)?
Weekly Report · 01/08 11:06
More
Webull provides a variety of real-time ONVO stock news. You can receive the latest news about Organovo Holding through multiple platforms. This information may help you make smarter investment decisions.
About ONVO
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.